

(19) AUSTRALIAN PATENT OFFICE

(54) Title
2H or 3H-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof

(51)⁶ International Patent Classification(s)
C07D 231/54 4BHAU **A61K**
(2006.01) 31/416
A61K 31/416 20060101ALI2005100
(2006.01) 8BMEP **C07D**
C07D 231/56 231/56
(2006.01) 20060101ALI2005100
C07D 401/12 8BMEP **C07D**
(2006.01) 401/12
C07D 231/54 20060101ALI2005100
20060101AFI2006090 8BMEP
PCT/FR2005/001154

(21) Application No: 2005251982 (22) Application Date: 2005 .05 .10

(87) WIPO No: W005/121099

(30) Priority Data

(31) Number	(32) Date	(33) Country
0405055	2004 .05 .11	FR

(43) Publication Date : 2005 .12 .22

(71) Applicant(s)
Sanofi-Aventis

(72) Inventor(s)
Evanno, Yannick, Maloizel, Christian, Sevrin, Mireille, Dubois, Laurent

(74) Agent/Attorney
Davies Collison Cave, 1 Nicholson Street, Melbourne, VIC, 3000

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION
EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété
Intellectuelle
Bureau international



(43) Date de la publication internationale
22 décembre 2005 (22.12.2005)

PCT


(10) Numéro de publication internationale
WO 2005/121099 A1

- (51) Classification internationale des brevets⁷ :
C07D 231/54
- (21) Numéro de la demande internationale :
PCT/FR2005/001154
- (22) Date de dépôt international : 10 mai 2005 (10.05.2005)
- (25) Langue de dépôt : français
- (26) Langue de publication : français
- (30) Données relatives à la priorité :
0405055 11 mai 2004 (11.05.2004) FR
- (71) Déposant (pour tous les États désignés sauf US) :
SANOFI-AVENTIS [FR/FR]; 174, avenue de France,
F-75013 Paris (FR).
- (72) Inventeurs; et
(75) Inventeurs/Déposants (pour US seulement) : DUBOIS,
Laurent [FR/FR]; 132, avenue de la Résistance, F 92350
Le Plessis-Robinson (FR). EVANNO, Yannick [FR/FR];
5, domaine des Aulnes, F-78830 Bullion (FR). MAL-
OIZEL, Christian [FR/FR]; 21, rue du Plateau, F-92190
Meudon (FR). SEVRIN, Mireille [FR/FR]; 3, rue Francis
de Pressensé, F-75014 Paris (FR).
- (74) Mandataire : GASLONDE, Aude; Sanofi-Aventis, 174,
avenue de France, F-75013 Paris (FR).
- (81) États désignés (sauf indication contraire, pour tout titre de
protection nationale disponible) : AE, AG, AL, AM, AT,
AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO,
CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW.
- (84) États désignés (sauf indication contraire, pour tout titre
de protection régionale disponible) : ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Suite sur la page suivante]

(54) Title: 2H OR 3H-BENZO[E]INDAZOL-1-YLE CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF

(54) Titre : DERIVES DE CARBAMATE DE 2H- OU 3H-BENZO[E]INDAZOL-1-YLE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE



(57) Abstract: The invention relates to compounds of formula (I), wherein W is an oxygen or sulphur atom, each X₂, X₃ and X₄ independently represents a hydrogen or halogen atom or a cyano, C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, C₁-C₆-alkoxy, C₁-C₆-fluoroalkoxy group, Y is in position (N2) or (N3); when Y is in the (N2) position, Y represents a C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, aryl or heteroaryl group; when Y is in the (N3) position, Y represents an aryl or heteroaryl group; the aryl and heteroaryl groups are possibly substituted by one or several atoms or groups selected from halogen atoms, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkyl-S(O)-, C₁-C₆-alkyl-S(O)₂-, C₁-C₆-fluoroalkyl groups; a C4-C5 position bond is double or single, each R₁ et R₂ independently represents an aryl, benzyl or C₁-C₆-alkyl group or R₁ et R₂ form, with a nitrogen atom carrier thereof, a heterocycle possibly substituted by one or several C₁-C₆-alkyl or benzyl groups in the form of a base, an acid addition salt, a hydrate or a solvate. A method for preparation and therapeutic use is also disclosed.

(57) Abrégé : L'invention concerne des composés de formule générale (I) : dans laquelle W représente un atome d'oxygène ou de soufre ; X₂, X₃ et X₄ représentent chacun, indépendamment l'un de l'autre, un atome d'hydrogène ou d'halogène ou un groupe cyano, C₁-C₆-alkyle, C₁-C₆-fluoroalkyle, C₁-C₆-alkoxy, C₁-C₆-fluoroalkoxy ; Y est en position (N2) ou (N3) ; quand Y est en position (N2), Y représente un groupe C₁-C₆-alkyle, C₁-C₆-fluoroalkyle, aryle ou hétéroaryle ; quand Y est en position (N3), Y représente un groupe aryle ou hétéroaryle ; les groupes aryle ou hétéroaryle étant éventuellement substitués par un ou plusieurs atomes ou groupes choisis parmi les atomes d'halogène, les groupes C₁-C₆-alkyle, C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkyl-S(O)-, C₁-C₆-alkyl-S(O)₂-, C₁-C₆-fluoroalkyle ; la liaison en position C4-C5 est double ou simple ; R₁ et R₂ représentent chacun, indépendamment l'un de l'autre, un groupe aryle, benzyle ou C₁-C₆-alkyle ; ou bien R₁ et R₂ forment, avec l'atome d'azote qui les porte un hétérocycle éventuellement substitué par un ou plusieurs groupes C₁-C₆-alkyle ou benzyle ; à l'état de base ou de sel d'addition à un acide, ainsi qu'à l'état d'hydrate ou de solvate. Procédé de préparation et application en thérapeutique.



européen (AT, BF, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

En ce qui concerne les codes à deux lettres et autres abréviations, se référer aux "Notes explicatives relatives aux codes et abréviations" figurant au début de chaque numéro ordinaire de la Gazette du PCT.

Publiée :

— avec rapport de recherche internationale

2H- or 3H-benzo[e]indazol-1-yl carbamate derivatives,
the preparation and therapeutic use thereof


A subject-matter of the invention is 2H- or
5 3H-benzo[e]indazol-1-yl carbamate derivative compounds
which exhibit an *in vitro* and *in vivo* affinity for
peripheral-type benzodiazepine receptors (PBR or p
sites).

A first subject-matter of the invention is
10 the compounds corresponding to the general formula (I)
below.

Another subject-matter of the invention is
processes for the preparation of the compounds of
general formula (I).

15 Another subject-matter of the invention is
the uses of the compounds of general formula (I), in
particular in medicaments or in pharmaceutical
compositions.

The compounds of the invention correspond to
20 the general formula (I):



in which

W represents an oxygen or sulphur atom;

X₁, X₂, X₃ and X₄ each represent, independently of one another, a hydrogen or halogen atom or a cyano,

5 C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, C₁-C₆-alkoxy or C₁-C₆-fluoroalkoxy group;

Y is in the (N2) or (N3) position;

when Y is in the (N2) position, Y represents a

C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, aryl or heteroaryl group;

10 when Y is in the (N3) position, Y represents an aryl or heteroaryl group;

the aryl or heteroaryl groups optionally being

substituted by one or more atoms or groups chosen from halogen atoms or C₁-C₆-alkyl, C₁-C₆-alkoxy,

15 C₁-C₆-alkylthio, C₁-C₆-alkyl-S(O)-, C₁-C₆-alkyl-S(O)₂- or C₁-C₆-fluoroalkyl groups;

the bond in the C4-C5 position is a double or single bond;

R₁ and R₂ each represent, independently of one another,

20 an aryl, benzyl or C₁-C₆-alkyl group; or else R₁ and R₂

form, with the nitrogen atom which carries them, a

heterocycle optionally substituted by one or more C₁-C₆-alkyl or benzyl groups.

In the context of the present invention:

25 - C_t-C_z, where t and z can take the values from 1 to 6, is understood to mean a carbon chain which can have from t to z carbon atoms, for example C₁₋₃, a carbon

- chain which can have from 1 to 3 carbon atoms;
- an alkyl is understood to mean a saturated, linear or branched, aliphatic group. Mention may be made, by way of examples, of the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or pentyl groups, and the like;
 - a fluoroalkyl is understood to mean an alkyl group, one or more hydrogen atoms of which have been substituted by a fluorine atom;
- 10 - an alkoxy is understood to mean an -O-alkyl radical where the alkyl group is as defined above;
- a fluoroalkoxy is understood to mean an alkoxy group, one or more hydrogen atoms of which have been substituted by a fluorine atom;
- 15 - an alkylthio is understood to mean an -S-alkyl radical where the alkyl group is as defined above;
- a heterocycle is understood to mean a 4- to 7-membered cyclic group comprising a nitrogen atom and optionally another heteroatom, such as nitrogen, oxygen or sulphur. Mention may be made, as examples of heterocycles, of the azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, azepinyl, piperazinyl or homopiperazinyl groups;
 - an aryl is understood to mean an aromatic cyclic group comprising between 6 and 10 carbon atoms. Mention may be made, as examples of aryl groups, of the phenyl or naphthyl groups;

- a heteroaryl is understood to mean a 5- or 6-membered aromatic cyclic group comprising 1 or 2 heteroatoms, such as nitrogen, oxygen or sulphur. Mention may be made, as examples of heteroaryl groups, of the pyridyl, thienyl, furyl, pyrimidinyl, pyrazinyl or pyridazinyl groups;
- a member is understood to mean, in a cyclic group, an atom connected between the two adjacent atoms of the ring;
- 10 - a halogen atom is understood to mean a fluorine, a chlorine, a bromine or an iodine.

The compounds of general formula (I) can comprise one or more asymmetric carbons. They can exist in the form of enantiomers or of diastereoisomers.

- 15 These enantiomers and diastereoisomers, and their mixtures, including the racemic mixtures, form part of the invention.

- The compounds of formula (I) can exist in the form of bases or of addition salts with acids. Such
- 20 addition salts form part of the invention.

- These salts are advantageously prepared with pharmaceutically acceptable acids but the salts of other acids, for example of use in the purification or the isolation of the compounds of formula (I), also
- 25 form part of the invention.

The compounds of general formula (I) can exist in the form of hydrates or of solvates, namely in

the form of combinations or associations with one or more molecules of water or with a solvent. Such hydrates and solvates also form part of the invention.

- Among the compounds of formula (I) which are
- 5 subject-matters of the invention, a first subgroup of compounds is composed of the compounds for which:
- W represents an oxygen or sulphur atom; and/or
- X₁, X₂ and X₃ each represent, independently of one another, a hydrogen atom, a halogen atom, more
- 10 particularly a fluorine, chlorine or bromine atom, a cyano group, a C₁-C₆-alkyl group, more particularly a methyl group, or a C₁-C₆-alkoxy group, more particularly a methoxy group; and/or
- X₄ represents a hydrogen atom; and/or
- 15 Y is in the (N2) or (N3) position;
- when Y is in the (N2) position, Y represents a C₁-C₆-alkyl group, more particularly a methyl or ethyl group, a C₁-C₆-fluoroalkyl group, more particularly a trifluoroethyl group, an aryl group, more particularly
- 20 a phenyl group, or a heteroaryl group, more particularly a pyridyl or pyrazinyl group;
- when Y is in the (N3) position, Y represents an aryl group, more particularly a phenyl group, or a heteroaryl group, more particularly a pyridyl or
- 25 pyrimidinyl group;
- the aryl or heteroaryl groups optionally being substituted by one or more atoms or groups, more

- particularly by one or two atoms or groups, chosen from halogen atoms, more particularly fluorine or chlorine atoms, C₁-C₆-alkyl groups, more particularly methyl groups, and C₁-C₆-alkoxy groups, more particularly
- 5 methoxy groups; and/or
- the bond in the C4-C5 position is a double or single bond; and/or
- R₁ and R₂ each represent, independently of one another, an aryl group, more particularly a phenyl group, or a
- 10 C₁-C₆-alkyl group, more particularly a methyl, ethyl, n-propyl, t-butyl or isopropyl group; or else R₁ and R₂ form, with the nitrogen atom which carries them, a heterocycle, more particularly pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, optionally
- 15 substituted by one or two C₁-C₆-alkyl groups, more particularly methyl groups.

Among the compounds of formula (I) which are subject-matters of the invention, a second subgroup of compounds is composed of the compounds for which:

- 20 W represents an oxygen or sulphur atom; and/or
- X₁, X₂ and X₃ each represent, independently of one another, a hydrogen atom, a halogen atom, more particularly a fluorine, chlorine or bromine atom, a C₁-C₆-alkyl group, more particularly a methyl group, or
- 25 a C₁-C₆-alkoxy group, more particularly a methoxy group; and/or
- X₄ represents a hydrogen atom; and/or

- Y is in the (N2) or (N3) position and represents an aryl group, more particularly a phenyl group, or a heteroaryl group, more particularly a pyridyl, pyrazinyl or pyrimidinyl group;
- 5 the aryl or heteroaryl groups optionally being substituted by one or more atoms or groups, more particularly by one or two atoms or groups, chosen from halogen atoms, more particularly fluorine or chlorine atoms, C₁-C₆-alkyl groups, more particularly methyl
- 10 groups, and C₁-C₆-alkoxy groups, more particularly methoxy groups; and/or the bond in the C4-C5 position is a double or single bond; and/or
- R₁ and R₂ each represent, independently of one another,
- 15 an aryl group, more particularly a phenyl group, or a C₁-C₆-alkyl group, more particularly a methyl, ethyl, n-propyl, t-butyl or isopropyl group; or else R₁ and R₂ form, with the nitrogen atom which carries them, a heterocycle, more particularly pyrrolidinyl,
- 20 piperidinyl, morpholinyl or piperazinyl, optionally substituted by one or two C₁-C₆-alkyl groups, more particularly methyl groups.

Among the compounds of formula (I) which are subject-matters of the invention, a third subgroup of

25 compounds is composed of the compounds for which:

W represents an oxygen or sulphur atom; and/or

X₁, X₂ and X₃ each represent, independently of one

another, a hydrogen atom, a halogen atom, more particularly a fluorine, chlorine or bromine atom, a C₁-C₆-alkyl group, more particularly a methyl group, or a C₁-C₆-alkoxy group, more particularly a methoxy group;
5 and/or

X₄ represents a hydrogen atom; and/or
Y is in the (N3) position and represents an aryl group, more particularly a phenyl group, or a heteroaryl group, more particularly a pyridyl or pyrimidinyl
10 group;

the aryl or heteroaryl groups optionally being substituted by one or more atoms or groups, more particularly by one or two atoms or groups, chosen from halogen atoms, more particularly fluorine or chlorine
15 atoms, C₁-C₆-alkyl groups, more particularly methyl groups, and C₁-C₆-alkoxy groups, more particularly methoxy groups; and/or
the bond in the C4-C5 position is a double or single bond; and/or

20 R₁ and R₂ each represent, independently of one another, an aryl group, more particularly a phenyl group, or a C₁-C₆-alkyl group, more particularly a methyl, ethyl, t-butyl or isopropyl group; or else R₁ and R₂ form, with the nitrogen atom which carries them, a heterocycle,
25 more particularly piperidinyl, optionally substituted by one or two C₁-C₆-alkyl groups, more particularly methyl groups.


The compounds of general formula (I) can be prepared by the processes illustrated in the following schemes.

According to a first preparation route
5 (Scheme 1), a compound of general formula (II), in which X_1 , X_2 , X_3 and X_4 are as defined in the general formula (I), is reacted with methyl carbonate in the presence of a catalytic amount of a base, such as sodium methoxide or sodium hydride, to obtain the
10 ketoester of general formula (III). The condensation of the ketoester (III) with hydrazine, for example in a polar solvent, such as DMF or acetic acid, makes it possible to isolate the pyrazole of general formula (IV). The latter is subsequently N-substituted
15 nonselectively by the action of an aryl or heteroaryl halide of general formula Y-hal, in which Y is as defined in the general formula (I) and hal is a halogen atom, such as an iodine or a bromine, in the presence of a base, such as potassium or caesium carbonate, or
20 of potassium triphosphate, of a catalytic amount of a copper salt and of a diamine (S.L. Buchwald, *J. Am. Chem. Soc.*, **2001**, 123, 7727).

The resulting mixture composed of the positional isomers of general formulae (Va) and (Vb),
25 in which the Y group is respectively in the 2-position and in the 3-position of the pyrazole ring, is subsequently derivatized by the action of a carbamoyl

chloride derivative of general formula $\text{ClC(W)NR}_1\text{R}_2$, in which W, R_1 and R_2 are as defined in the general formula (I), in the presence of a base, such as potassium carbonate, sodium hydride or triethylamine, to obtain
5 the carbamates of general formulae (Ia) and (Ib), which are separated, at this stage, by methods known to a person skilled in the art, such as chromatography on a silica column.


Scheme 1



Alternatively, a second preparation route makes it possible to prepare the compounds of general formula (Ia) (Scheme 2).

Scheme 2

5



It consists in condensing the ketoester of general formula (III), as defined above, with a hydrazine of general formula $Y-NH-NH_2$, in which Y is as defined in the general formula (I), for example in a

polar solvent, such as DMF or acetic acid, and makes it possible to isolate the pyrazole of general formula (Va), as defined above. The latter is subsequently acylated by the action of a carbamoyl chloride derivative of general formula $\text{ClC(W)NR}_1\text{R}_2$, as defined above, in the presence of a base, such as potassium carbonate, sodium hydride or triethylamine, to obtain the carbamate of general formula (Ia).

The single bond in the C4-C5 position of the compounds of general formula (I) can optionally be dehydrogenated to form a double bond according to a method known to a person skilled in the art, for example by analogy with the method described by Kozo, Shishido et al., *Tetrahedron*, **1989**, 45, 18, 5791-5804.

Alternatively, the compounds of general formula (I) comprising a single bond in the C4-C5 position can be dehydrogenated by reaction with a halogenating agent, such as N-bromosuccinimide, in the presence of an initiator, such as 2,2'-azobis(2-methylpropionitrile).

Under these conditions, the compound of general formula (I) comprising a single bond in the C4-C5 position is first halogenated and then the resulting intermediate is subjected to an elimination reaction to result in the compound (I) comprising a double bond in the C4-C5 position.

In Schemes 1 and 2, the reactants, when their method of preparation is not described, are

commercially available or are described in the literature or else can be prepared according to methods which are described therein or which are known to a person skilled in the art.


5 The compounds of general formula (II) can be obtained from commercial sources or can be prepared using methods described in the literature (Sims, J.J. et al., *Tetrahedron Lett.*, 1971, 951).

 Another subject-matter of the invention,
10 according to another of its aspects, is the compounds of formulae (Va) and (Vb). These compounds may be of use as intermediates in the synthesis of the compounds of formula (I).

 The chemical structures and the physical
15 properties of a few compounds of general formulae (Va) and (Vb) of the invention are illustrated in the following Table 1. The melting points of the products are given in the "M.p." column.

Table 1

20



No.	X ₁	X ₂	X ₃	X ₄	Y	M.p. (°C)
Va.1	H	H	H	H	2-(4-methylphenyl)	221-222
Vb.1	H	Me	H	H	3-(pyrid-4-yl)	315-316
Va.2	H	F	H	H	2-(4-fluorophenyl)	220-221
Vb.2	H	Cl	H	H	3-(pyrid-4-yl)	336 - 342
Va.3	H	Cl	H	H	2-(pyrid-4-yl)	190 - 216

The preparation of some compounds in accordance with the invention is described in the following examples. These examples are not limiting and only illustrate the present invention. The numbers of the compounds exemplified refer to those given in Tables 1 and 2. The elemental microanalyses, the LC-MS (liquid chromatography coupled to mass spectrometry) analyses and the IR and NMR spectra confirm the structures of the compounds obtained.

Example 1 (Compound No. 1)

7-Fluoro-2-(4-fluorophenyl)-4,5-dihydro-2H-benzo[e]indazol-1-yl N,N-diethylcarbamate

1.1 Methyl 6-fluoro-2-hydroxy-3,4-dihydro-1-naphthoate

12.66 g (316 mmol) of 60% sodium hydride in oil, 900 ml of toluene and 17.69 ml (210 mmol) of dimethyl carbonate are introduced into a 2 l reactor.

The reaction mixture is stirred at reflux for 1 h. A solution of 19 g (115 mmol) of 6-fluoro-3,4-dihydro-1H-naphthalen-2-one in 350 ml of toluene is subsequently

added. The reaction mixture is heated at reflux for 24 h. The reaction mixture is subsequently cooled to 0°C and then acidified by addition of 114 ml of acetic acid. 114 ml of water are added and the separated organic phase is separated by settling and washed with two times 150 ml of water and then with 100 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure to result in 26.1 g of a product which is used as is in the following stage.

1.2 7-Fluoro-2-(4-fluorophenyl)-1-hydroxy-4,5-dihydro-2H-benzo[e]indazole (Va.2)

2 g (9 mmol) of the product obtained in Stage 1.1 and 2.73 g (16.8 mmol) of 4-fluorophenylhydrazine hydrochloride are introduced into a 100 ml reactor. The mixture is dissolved in 100 ml of acetic acid and heated at reflux for 4 h. The reaction mixture is subsequently cooled and then concentrated under reduced pressure. The residue is taken up in 150 ml of ethyl acetate and 100 ml of water. The organic phase is separated by settling and washed twice with 100 ml of water and then once with 100 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure to result in 3.5 g of the expected compound.

Melting point: 220-221°C

¹H NMR (d₆-DMSO): δ (ppm): 2.72 (dxd, 2H), 2.95 (dxd, 2H), 7.01 (m, 2H), 7.3 (m, 2H), 7.75 (m, 3H).

1.3 7-Fluoro-2-(4-fluorophenyl)-4,5-dihydro-
5 2H-benzo[e]indazol-1-yl N,N-diethylcarbamate
(Compound No. 1)

3.5 g (9 mmol) of the product obtained in
Stage 1.2, 3.48 g (25 mmol) of potassium carbonate and
2.66 ml (21 mmol) of N,N-diethylcarbamoyl chloride are
10 introduced into a 500 ml reactor. The reaction mixture
is heated at reflux for 24 h and is then concentrated
under reduced pressure. The resulting product is taken
up in 100 ml of ethyl acetate. The organic phase is
washed twice with 100 ml of water and then once with
15 100 ml of a saturated aqueous sodium chloride solution.
The organic phase is subsequently dried over magnesium
sulphate and then concentrated under reduced pressure
to result in 5.96 g of crude product. The mixture is
purified by chromatography on a silica column, elution
20 being carried out with a mixture of cyclohexane and
ethyl acetate. 2.2 g of the expected product are thus
isolated and recrystallized from isopropanol to produce
1.5 g (3.77 mmol) of the final product.

Melting point: 141-142°C

25 ¹H NMR (CDCl₃): δ (ppm): 1.95 (t, 3H), 2.6 (t, 3H), 2.97
(t, 2H), 3.98 (t, 2H), 3.4 (q, 2H), 3.52 (q, 2H), 7.00
(m, 2H), 7.2 (m, 2H), 7.32 (m, 1H), 7.56 (m, 2H).

Example 2 (Compound No. 2)

7-Fluoro-2-(4-fluorophenyl)-2*H*-benzo[e]indazol-1-yl
N,N-diethylcarbamate

- 5 A solution of 0.7 g (1.76 mmol) of
7-fluoro-2-(4-fluorophenyl)-4,5-dihydro-2*H*-
benzo[e]indazol-1-yl N,N-diethylcarbamate, obtained in
Stage 1.3 of Example 1, and of 1.2 g (5.2 mmol) of 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone in 25 ml of
10 toluene is stirred at reflux for 2 h and then cooled.
The mixture is poured onto 100 ml of ethyl acetate.
This organic phase is washed with two times 100 ml of a
saturated aqueous sodium hydrogencarbonate solution,
with 100 ml of water and then with 100 ml of a
15 saturated aqueous sodium chloride solution. The organic
phase is separated by settling, then dried over
magnesium sulphate and concentrated under reduced
pressure. After purification by chromatography on a
silica column (eluent: mixture of methylene chloride
20 and of ethyl acetate) and recrystallization from
isopropanol, 500 mg (1.26 mmol) of the expected product
are obtained.

Melting point: 159-160°C

- ¹H NMR (d₆-DMSO): δ (ppm): 1.04 (t, 3H), 1.21 (t, 3H),
25 3.28 (q, 2H), 3.55 (q, 2H), 7.45 (m, 3H), 7.7 (m, 5H),
7.9 (dxd, 1H).

Example 3 (Compounds Nos 3 and 4)

7-Chloro-2-(pyrid-4-yl)-4,5-dihydro-2H-benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride (Compound No. 3) and 7-chloro-3-(pyrid-4-yl)-4,5-dihydro-3H-benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride (Compound No. 4)

3.1 Methyl 6-chloro-2-hydroxy-3,4-dihydro-1-naphthoate

10.1 g (252 mmol) of 60% sodium hydride in oil, 621 ml of toluene and 14.18 ml (163 mmol) of dimethyl carbonate are introduced into a 2 l reactor. The reaction mixture is stirred at reflux for 1 h. A solution of 15.2 g (84 mmol) of 6-chloro-3,4-dihydro-1H-naphthalen-2-one in 268 ml of toluene is subsequently added. The reaction mixture is heated at reflux for 24 h. The reaction mixture is subsequently cooled to 0°C and then acidified by addition of 92 ml of acetic acid. 114 ml of water are added and the separated organic phase is separated by settling and washed with three times 150 ml of water and then with 100 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. The residue is purified by chromatography on a silica column (elution being carried out with a mixture of cyclohexane and of dichloromethane) to result in 12.8 g (53.6 mmol) of the expected product used as is in the

following stage.

3.2 7-Chloro-1-hydroxy-4,5-dihydro-2H-benzo[e]indazole

28 g (117 mmol) of the product obtained in Stage 3.1 and 28.6 ml (586.6 mmol) of hydrazine monohydrate are introduced into a 2 l reactor. The mixture is dissolved in 782 ml of acetic acid and heated at reflux for 4 h. The reaction mixture is subsequently cooled and then concentrated under reduced pressure. The resulting product is taken up in 300 ml of ethyl acetate and 300 ml of water. The organic phase is separated by settling and washed twice with 200 ml of water and then once with 200 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. The residue obtained is triturated from 200 ml of ethyl ether and then filtered off to result in 25 g (113.3 mol) of the expected product.

20 Melting point: 232-233°C

3.3 7-Chloro-1-hydroxy-2-(pyrid-4-yl)-4,5-dihydro-2H-benzo[e]indazole and 7-chloro-1-hydroxy-3-(pyrid-4-yl)-4,5-dihydro-3H-benzo[e]indazole

15.2 g (68.8 mmol) of the product obtained in Stage 3.2, 16.95 g (82.66 mmol) of 4-iodopyridine, 4.14 ml (34.44 mmol) of trans-1,2-diaminocyclohexane, 1.31 g (6.89 mmol) of copper iodide and 36.55 g

(172.2 mmol) of potassium phosphate are introduced under an inert atmosphere into a 2 l reactor. The reaction mixture is suspended in 690 ml of dioxane, brought to reflux for 24 h and then cooled. The mixture is concentrated under reduced pressure and then taken up in 200 ml of water. This aqueous phase is acidified to pH 5 by successive additions of acetic acid. The suspension is stirred for 30 minutes and then the precipitate obtained is filtered off, washed with water and then dried under reduced pressure to produce 16.6 g (55.7 mmol) of the expected N-arylation product in the form of a mixture of isomers.

LC-MS: 2 peaks at 60.4% and 38% corresponding to $[MH]^+ = 298$.

3.4 7-Chloro-2-(pyrid-4-yl)-4,5-dihydro-2H-benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride (Compound No. 3) and 7-chloro-3-(pyrid-4-yl)-4,5-dihydro-3H-benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride (Compound No. 4)

13 g (43.66 mmol) of the mixture of isomers obtained in Stage 3.3, 18.1 g (131 mmol) of finely ground potassium carbonate and 11.07 ml (87.32 mmol) of N,N-diethylcarbamoyl chloride are introduced, under an inert atmosphere, into a 2 l reactor. The reaction mixture is suspended in 1 l of acetonitrile, brought to reflux for 24 h and then cooled. The reaction mixture is concentrated under reduced pressure. The resulting

product is taken up in 300 ml of ethyl acetate and 300 ml of water. The organic phase is separated by settling and washed twice with 200 ml of water and once with 200 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. The resulting product comprises the two positional isomers (Compounds Nos 3 and 4). The latter are separated by column chromatography (300 g of Merck 15-40 microns silica, eluents: mixture of heptane and of ethyl acetate).

7-Chloro-2-(pyrid-4-yl)-4,5-dihydro-2H-benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride (Compound No. 3)

Product No. 3, thus isolated, is converted to the hydrochloride by dissolving in a 0.1N solution of hydrochloric acid in isopropanol. The solution is concentrated to dryness under reduced pressure. After triturating from ethyl ether, filtering and drying under reduced pressure, 2.3 g (5.79 mmol) of the final product are obtained.

Melting point: 250-251°C

¹H NMR (d₆-DMSO): δ (ppm): 1.08 (t, 3H), 1.31 (t, 3H), 2.98 (m, 4H), 3.3 (q, 2H), 3.68 (q, 3H), 7.27 (d, 1H), 7.38 (dxd, 1H), 7.46 (dxd, 1H), 7.92 (d, 2H), 8.87 (d, 2H).

7-Chloro-3-(pyrid-4-yl)-4,5-dihydro-3H-

benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride
(Compound No. 4)

Product No. 4, thus isolated, is converted to the hydrochloride by dissolving in a 0.1N solution of hydrochloric acid in isopropanol. The solution is concentrated to dryness under reduced pressure. After triturating from ethyl ether, filtering and drying under reduced pressure, 6.2 g (15.62 mmol) of the final product are obtained.

10 Melting point: 224-226°C

¹H NMR (d₆-DMSO): δ (ppm): 1.18 (t, 3H), 1.29 (t, 3H), 3.02 (t, 2H), 3.31 (m, 4H), 3.51 (q, 2H), 7.20 (d, 1H), 7.32 (dxd, 1H), 7.45 (d, 1H), 8.08 (d, 2H), 8.98 (d, 2H).

15

Example 4 (Compound No. 5)

8-Methoxy-3-(pyrid-4-yl)-4,5-dihydro-3H-

benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride

4.1 Methyl 6-methoxy-2-hydroxy-3,4-dihydro-1-naphthoate

3.4 g (85.12 mmol) of 60% sodium hydride in oil, 180 ml of toluene and 4.78 ml (56.75 mmol) of dimethyl carbonate are introduced into a 1 l reactor. The reaction mixture is stirred at reflux for 1 h. A solution of 5 g (28.37 mmol) of 7-methoxy-3,4-dihydro-1H-naphthalen-2-one in 100 ml of toluene is subsequently added. The reaction mixture is heated at

reflux for 24 h. The reaction mixture is subsequently cooled to 0°C and then acidified by addition of 30 ml of acetic acid. 30 ml of water are added and the separated organic phase is separated by settling and
5 washed with two times 50 ml of water and then with 50 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. After purification by chromatography on a silica column
10 (eluent: mixture of methylene chloride and of heptane), 3.9 g (16.64 mmol) of the expected product are obtained and are used as in the following stage.

4.2 1-Hydroxy-8-methoxy-4,5-dihydro-2H-benzo[e]indazole

15 3.9 g (16.65 mmol) of the product obtained in Stage 4.1 and 4.06 ml (83.24 mmol) of hydrazine monohydrate are introduced into a 0.5 l reactor. The mixture is dissolved in 166 ml of acetic acid and heated at reflux for 4 h. The reaction mixture is
20 subsequently cooled and then concentrated under reduced pressure. The resulting product is taken up in 100 ml of ethyl acetate and 100 ml of water. The organic phase is separated by settling and washed twice with 100 ml of water and then once with 100 ml of a saturated
25 aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. The residue

obtained is triturated from 50 ml of ethyl ether and then filtered off to result in 2.4 g (11.1 mmol) of the expected product.

4.3 1-Hydroxy-8-methoxy-3-(pyrid-4-yl)-4,5-dihydro-3H-benzo[e]indazole

1.2 g (5.55 mmol) of the product obtained in Stage 4.2, 1.36 g (6.66 mmol) of 4-iodopyridine, 0.33 ml (2.77 mmol) of trans-1,2-diaminocyclohexane, 0.105 g (0.55 mmol) of copper iodide and 2.94 g (13.87 mmol) of potassium phosphate are introduced, under an inert atmosphere, into a 0.1 l reactor. The reaction mixture is suspended in 55 ml of dioxane, brought to reflux for 24 h and then cooled. The mixture is subsequently taken up in 1 l of a 1/1 mixture of water and of ethyl acetate. The organic phase is separated by settling and then washed with water (50 ml). This aqueous phase is acidified to pH 5 by successive additions of acetic acid. The precipitate obtained is filtered off, washed with water and then dried under reduced pressure to produce 0.2 g (0.68 mmol) of the expected N-arylation product. The organic phase is dried over magnesium sulphate and then concentrated under reduced pressure. The resulting product is purified by chromatography on a silica column (eluents: mixture of dichloromethane and methanol) to produce an additional 0.57 g (1.94 mmol) of the expected N-arylation product.

^1H NMR (d_6 -DMSO): δ (ppm): 2.89 (dxd, 2H), 3.09 (dxd, 2H), 3.73 (s, 3H), 6.2 (dxd, 1H), 7.1 (m, 2H), 7.48 (m, 2H), 8.6 (m, 2H).

4.4 8-Methoxy-3-(pyrid-4-yl)-4,5-dihydro-3H-benzo[e]indazol-1-yl N,N-diethylcarbamate hydrochloride (Compound No. 5)

0.77 g (2.63 mmol) of the product obtained in Stage 4.3, 1.09 g (7.88 mmol) of finely ground potassium carbonate and 0.67 ml (5.25 mmol) of N,N-diethylcarbamoyl chloride are introduced, under an inert atmosphere, into a 0.1 l reactor. The reaction mixture is suspended in 30 ml of acetonitrile, brought to reflux for 24 h and then cooled. The reaction mixture is concentrated under reduced pressure. The resulting product is taken up in 100 ml of ethyl acetate and 100 ml of water. The organic phase is separated by settling and washed twice with 50 ml of water and then once with 50 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. The resulting product is purified by column chromatography (90 g of Merck 15-40 microns silica, eluents: mixture of heptane and of ethyl acetate). The compound thus isolated is recrystallized from isopropanol and then redissolved in a 0.1N solution of hydrochloric acid in isopropanol. The solution is concentrated to dryness under reduced

pressure. After triturating from ethyl ether, filtering off and drying under reduced pressure, 234 mg (0.59 mmol) of the expected compound are obtained.

Melting point: 225-227°C

5 ¹H NMR (d₆-DMSO): δ (ppm): 1.15 (t, 3H), 1.3 (t, 3H), 2.92 (t, 2H), 3.2-3.4 (m, 4H), 3.51 (q, 2H), 3.71 (s, 3H), 6.8 (m, 2H), 7.2 (d, 1H), 7.98 (d, 2H), 8.82 (d, 2H).

10 **Example 5** (Compound No. 82)

7-Chloro-4,5-dihydro-3-(pyrid-4-yl)-3H-benzo[e]indazol-1-yl N,N-diisopropylcarbamate hydrochloride

2.3 g (7.72 mmol) of the mixture of isomers obtained in Stage 3.3 of Example 3, in solution in 15 30 ml of dimethylformamide, are added dropwise, under an inert atmosphere and at 0°C, to a suspension of 0.4 g (10.04 mmol) of sodium hydride in 17 ml of dimethylformamide in a 1 l reactor. After stirring at ambient temperature for 1 hour, 1.39 g (8.5 mmol) of 20 N,N-diisopropylcarbamoyl chloride in 30 ml of dimethylformamide are added dropwise. The reaction mixture is stirred at ambient temperature for 18 h and is then concentrated under reduced pressure. The resulting product is taken up in 300 ml of ethyl 25 acetate and 300 ml of water. The aqueous phase is brought to pH 5 by addition of acetic acid. The organic phase is separated by settling and washed twice with

200 ml of water and then once with 200 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. The resulting product is purified by column chromatography (300 g of Merck 15-40 microns silica, eluents: mixture of dichloromethane and of ethyl acetate). The product thus isolated is converted to the hydrochloride by dissolution in a 0.1N solution of hydrochloric acid in isopropanol. The solution is concentrated to dryness under reduced pressure. After triturating from ethyl ether, filtering off and drying under reduced pressure, 1.2 g (2.6 mmol) of the final product are obtained. Melting point: 237-269°C

¹H NMR (d₆-DMSO): δ (ppm): 1.29 (m, 12H), 3.02 (m, 2H), 3.19 (m, 2H), 3.91 (m, 1H), 4.2 (m, 1H), 7.2 (d, 1H), 7.35 (dxd, 1H), 7.42 (s, 1H), 7.6 (d, 2H), 8.7 (d, 2H).

Example 6 (Compound No. 84)

7-Chloro-3-(pyrid-4-yl)-3H-benzo[e]indazol-1-yl N,N-diisopropylcarbamate hydrochloride

1.65 g (3.38 mmol) of 7-chloro-4,5-dihydro-3-(pyrid-4-yl)-3H-benzo[e]indazol-1-yl N,N-diisopropylcarbamate, prepared according to the method described in Example 5, 1.105 g (6.21 mmol) of N-bromosuccinimide and 0.127 g (0.78 mmol) of 2,2'-azobis(2-methylpropionitrile) are added to a 100 ml reactor. The

mixture, dissolved in 40 ml of carbon tetrachloride, is stirred at reflux for 24 h and is then concentrated under reduced pressure. The resulting product is taken up in 300 ml of dichloromethane and 2 ml of a concentrated aqueous ammonia solution. The organic phase is separated and washed with 200 ml of water and then with 200 ml of a saturated aqueous sodium chloride solution. The organic phase is subsequently dried over magnesium sulphate and then concentrated under reduced pressure. The resulting product is purified by chromatography on an alumina column (eluents: mixture of dichloromethane and of methanol) and then on a silica column (eluents: mixture of dichloromethane and of ethyl acetate). The product thus isolated is converted to the hydrochloride by dissolution in a 0.1N solution of hydrochloric acid in isopropanol. The solution is concentrated to dryness under reduced pressure. After triturating from ethyl ether, filtering off and drying under reduced pressure, 1.2 g (2.6 mmol) of the final product are obtained.

Melting point: 234-248°C


^1H NMR (d_6 -DMSO): δ (ppm): 1.42 (m, 12H), 4.02 (m, 1H), 4.41 (m, 1H), 7.6 (dxd, 1H), 7.8 (m, 3H), 7.92 (d, 2H), 8.15 (d, 1H), 8.79 (d, 2H).

The chemical structures and the physical properties of a few compounds of general formula (I) according to the invention are illustrated in the

following Table 2.

In the "Salt" column of this table, "HCl" denotes a hydrochloride and "-" denotes a compound in the base state. The base:acid molar ratios are shown opposite. The "M.p." column gives the melting points of the products, the amorphous compounds being characterized by their mass spectrometry (MS) analytical results.

Table 2



No.	X ₁	X ₂	X ₃	X ₄	W	NR ₁ R ₂	C4-C5 bond	Y	Salt	M.p. (°C)
1	H	F	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-fluorophenyl)	-	141-142
2	H	F	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(4-fluorophenyl)	-	159-160
3	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(pyrid-4-yl)	HCl 1:1	250-251
4	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-4-yl)	HCl	224-

No.	X ₁	X ₂	X ₃	X ₄	W	NR ₁ R ₂	C4-C5 bond	Y	Salt	M.p. (°C)
									1:1	226
5	H	H	OCH ₃	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-4-yl)	HCl 1:1	225-227
6	H	H	H	H	O	N(CH ₃) ₂	single	2-(4-methylphenyl)	-	130-131
7	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-chlorophenyl)	-	148-149
8	H	H	H	H	O		single	2-(3-chlorophenyl)	-	150-151
9	H	H	H	H	O	N(CH ₃) ₂	single	2-(3-chlorophenyl)	-	128-129
10	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(3-chlorophenyl)	-	111-113
11	H	H	H	H	O		single	2-(3-chlorophenyl)	-	155-157
12	H	H	H	H	O	N(CH(CH ₃) ₂) ₂	single	2-(3-chlorophenyl)	-	116-118
13	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-phenyl	-	124-125
14	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-phenyl	-	114-116
15	H	H	H	H	O	N(CH ₃)Ph	single	2-(3-chlorophenyl)	-	75-78
16	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(2-chlorophenyl)	-	396*
17	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-ethyl	-	60-61
18	H	H	H	H	O	N(CH ₃)Ph	single	2-ethyl	-	348*
19	H	H	H	H	O	N(CH ₃)Ph	single	2-(2,2,2-trifluoroethyl)	-	402*
20	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-fluorophenyl)	-	132-133
21	H	H	H	H	O	N(CH(CH ₃) ₂) ₂	single	2-(4-fluorophenyl)	-	95-96
22	H	H	H	H	O	N(CH ₃)Ph	single	2-(4-fluorophenyl)	-	197-198
23	H	H	H	H	O		single	2-(4-fluorophenyl)	-	211-212
24	H	H	H	H	O		single	2-(4-fluorophenyl)	-	174-175
25	H	H	H	H	O		single	2-(4-fluorophenyl)	-	175-176
26	H	H	H	H	O	N(CH ₃) ₂	single	2-(4-chlorophenyl)	-	211-212
27	H	H	H	H	O	N(CH(CH ₃) ₂) ₂	single	2-(4-chlorophenyl)	-	203-204
28	H	H	H	H	O	N(CH ₃)Ph	single	2-(4-chlorophenyl)	-	202-203
29	H	H	H	H	O		single	2-(4-chlorophenyl)	-	212-213
30	H	H	H	H	O		single	2-(4-chlorophenyl)	-	200-201

No.	X ₁	X ₂	X ₃	X ₄	W	NR ₁ R ₂	C4-C5 bond	Y	Salt	M.p. (°C)
31	H	H	H	H	O		single	2-(4-chlorophenyl)	-	185-186
32	H	H	H	H	O		single	2-(4-chlorophenyl)	-	157-158
33	H	H	H	H	O	N(CH ₃) ₂	single	2-(4-fluorophenyl)	-	216-217
34	H	H	H	H	O		single	2-(4-fluorophenyl)	-	167-168
35	H	H	H	H	O	N(CH ₃) ₂	single	2-phenyl	-	158-159
36	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-phenyl	-	146-147
37	H	H	H	H	O	N(CH ₃)Ph	single	2-phenyl	-	169-170
38	H	H	H	H	O		single	2-phenyl	-	176-177
39	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-fluorophenyl)	-	155-156
40	H	H	H	H	O	N(CH ₃)-(CH ₂) ₂ CH ₃	single	2-(4-fluorophenyl)	-	143-144
41	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(3-chloro-4-methylphenyl)	-	99-101
42	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(3-chloro-4-fluorophenyl)	-	148-150
43	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(3-chloro-4-methylphenyl)	-	131-133
44	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(2,4-difluorophenyl)	-	78-80
45	H	H	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(pyrid-4-yl)	HCl 1:1	298-299
46	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(pyrid-2-yl)	-	108-110
47	H	OCH ₃	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-fluorophenyl)	-	161-162
48	H	Br	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-fluorophenyl)	-	162-163
49	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(3-chloro-4-fluorophenyl)	-	108-110
50	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-methyl	-	117-118
51	H	H	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(3-chlorophenyl)	-	125-126
52	H	H	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(4-fluorophenyl)	-	125-126
53	H	H	H	H	O	N(CH ₃)(CH ₂) ₂ -CH ₃	double	2-(4-fluorophenyl)	-	154-155
54	H	H	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(3-chloro-4-fluorophenyl)	-	412*
55	H	H	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(3-chloro-4-methylphenyl)	-	116-120
56	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(4-fluorophenyl)	-	151-153
57	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(3-chloro-4-fluorophenyl)	-	141-143
58	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(3-chloro-4-	-	141-

No.	X ₁	X ₂	X ₃	X ₄	W	NR ₁ R ₂	C4-C5 bond	Y	Salt	M.p. (°C)
								methylphenyl)		143
59	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	double	2-(2,4-difluorophenyl)	-	144-146
60	H	OCH ₃	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-4-yl)	HCl 1:1	208-220
61	H	CH ₃	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-4-yl)	HCl 1:1	222-225
62	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-3-yl)	HCl 1:1	194-197
63	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(pyrid-3-yl)	HCl 1:1	155-157
64	H	F	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(pyrid-4-yl)	HCl 1:1	324-326
65	H	F	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-4-yl)	HCl 1:1	233-242
66	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(4-fluorophenyl)	-	131-132
67	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-2-yl)	HCl 1:1	122-123
68	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(3-fluorophenyl)	-	128-130
69	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(3-fluorophenyl)	-	124-126
70	H	Br	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(pyrid-4-yl)	HCl 1:1	300-310
71	H	Br	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-4-yl)	HCl 1:1	233-238
72	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(4-methylphenyl)	-	155-159
73	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-methylphenyl)	-	118-121
74	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(2-fluorophenyl)	-	414*
75	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(4-chlorophenyl)	-	177-178
76	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-chlorophenyl)	-	148-149
77	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	2-(4-methoxyphenyl)	-	131-132
78	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(4-methoxyphenyl)	-	185-187
79	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	double	3-(3-fluorophenyl)	-	142-144
80	H	Cl	H	H	O	N(CH ₃)Ph	single	3-(pyrid-4-yl)	-	213-215
81	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	single	2-(pyrid-4-yl)	-	184-185
82	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	single	3-(pyrid-4-yl)	-	146
									-	148
83	OCH ₃	H	H	H	O	N(CH ₂ CH ₃) ₂	single	3-(pyrid-4-yl)	HCl 1:1	237-269
									-	238-240
84	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	double	3-(pyrid-4-yl)	HCl 1:1	234-248

No.	X ₁	X ₂	X ₃	X ₄	W	NR ₁ R ₂	C4-C5 bond	Y	Salt	M.p. (°C)
85	H	Cl	H	H	O		single	2-(pyrid-4-yl)	HCl 1:1	153 - 173
86	H	Cl	H	H	O		single	3-(pyrid-4-yl)	HCl 1:1	243 - 248
87	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	single	2-(pyrid-3-yl)	HCl 1:1	243 - 260
88	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	single	3-(pyrid-3-yl)	HCl 1:1	209 - 213
89	H	Cl	H	H	S	N(CH(CH ₃) ₂) ₂	single	3-(pyrid-4-yl)	HCl 1:1	290 - 318
90	H	Cl	H	H	O		single	3-(pyrid-4-yl)	HCl 1:1	228 - 252
91	H	Cl	H	H	O	NCH ₂ C(CH ₃) ₃	single	2-(pyrid-4-yl)	HCl 1:1	350 - 360
92	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	double	3-(pyrid-3-yl)	HCl 1:1	238 - 240
93	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	single	3-(pyrid-2-yl)	-	193 - 195
94	H	F	H	H	O	N(CH(CH ₃) ₂) ₂	single	3-(pyrid-4-yl)	HCl 1:1	255 - 260
95	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	single	3-(pyrid-2-yl)	-	220 - 222
96	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	single	2-(pyrazin-2-yl)	-	175 - 176
97	H	F	H	H	O	N(CH(CH ₃) ₂) ₂	double	3-(pyrid-4-yl)	HCl 1:1	272 - 280
98	H	Cl	H	H	O	N(CH(CH ₃) ₂) ₂	double	3-(pyrid-2-yl)	-	213 - 215
99	H	Cl	H	H	O	N(CH ₃) - C(CH ₃) ₃	single	3-(pyrid-4-yl)	HCl 1:1	411*
100	H	Cl	H	H	O	N(CH ₂ CH ₃) ₂	double	3-(pyrid-4-yl)	HCl 1:1	227 - 229
101	H	Cl	H	H	O	N(CH ₃)Ph	double	3-(pyrid-4-yl)	HCl 1:1	248 - 268

* [MH]⁺

The compounds of the invention have been subjected to pharmacological tests which have demonstrated their advantage as substances with therapeutic activities.

The compounds of the invention also exhibit characteristics of solubility in water which promote good in vivo activity.

Study of the binding of [³H]Ro5-4864 to peripheral-type benzodiazepine receptors (PBR or p sites)

The affinity of the compounds of the invention for PBR or p sites (sites of binding of peripheral type to benzodiazepines) was determined.

The p site receptors can be labelled selectively in rat kidney membranes incubated in the presence of [³H]Ro5-4864. The compounds of the invention have formed the subject of an in vitro study with respect to their affinity for these receptors.

The animals used are male Sprague-Dawley rats (Iffa Credo) weighing 180 to 300 g. After decapitation, the kidney is removed and the tissue is homogenized at 4°C using a Polytron™ homogenizer for 2 min at 6/10 of the maximum speed in 35 volumes of 50 mM Na₂HPO₄ phosphate buffer at a pH adjusted to 7.5 with NaH₂PO₄. The membrane homogenate is filtered through gauze and diluted tenfold with buffer.

[³H]Ro5-4864 (specific activity: 70-90 Ci/mmol; New England Nuclear), at a concentration of 0.5 nM, is incubated in the presence of 100 µl of the membrane homogenate in a final volume of 1 ml of buffer comprising the test compound.

After incubating for 3 h at 0°C, the membranes are recovered by filtration through Whatman GF/B™ filters washed with 2 times 4.5 ml of cold (0°C)

incubation buffer. The amount of radioactivity retained by the filter is measured by liquid scintigraphy.

For each concentration of studied compound, the percentage of inhibition of the binding of ⁵ [3H]Ro5-4864 is determined and then the IC₅₀ concentration, the concentration which inhibits 50% of the specific binding, is determined.

The IC₅₀ values of the most active compounds of the invention range from 0.5 nM to 300 nM. In ¹⁰ particular, compounds Nos 14, 20 and 56 in Table 2 exhibit respective IC₅₀ values of 1.6 nM, 2.8 nM and 1.4 nM.

The compounds of the invention are therefore ¹⁵ ligands with an affinity for peripheral-type benzodiazepine receptors.

Study of the neuroprotective activity

Test of survival of the motor neurons after sectioning the facial nerve in rats aged 4 days

²⁰ After lesion of the facial nerve in immature rats, the motor neurons of the facial nucleus experience neuronal death by apoptosis. Neuronal survival is evaluated using neuronal counting and histological methods.

²⁵ Immature rats aged 4 days are anaesthetized with pentobarbital (3 mg/kg by the i.p. route). The right facial nerve is exposed and sectioned at its

outlet from the stylomastoid foramen. After waking up, the young rats are returned to their mothers and are treated for 7 days with one or two daily administrations, by the oral or intraperitoneal route, at doses ranging from 1 to 10 mg/kg.

7 days after the lesion, the animals are decapitated and the brains are frozen in isopentane at -40°C. The entire facial nerve is cut with a cryostat into sections with a width of 10 µm. The motor neurons are stained with cresyl violet and counted using the Histo™ software (Biocom™).

In this model, the compounds of the invention increase neuronal survival by 38 to 78%. The results of the test of survival of the motor neurons for compounds Nos 14, 20 and 56 of the table are presented in Table 3 below.

Table 3

No.	14	20	56
% increase in the survival of the neurons (10 mg/kg po)	38%	59%	74%

The results of the tests show that the most active compounds of the invention promote neuroprotection.

The compounds of the invention can thus be used for the preparation of medicaments, in particular

for the preparation of a medicament intended to prevent or treat a pathology in which peripheral-type benzodiazepine receptors are involved.

Thus, according to another of its aspects, a
5 subject-matter of the invention is medicaments which comprise a compound of formula (I), or an addition salt of the latter with a pharmaceutically acceptable acid, or a hydrate or a solvate.

These medicaments are employed in
10 therapeutics, in particular in the prevention and/or treatment of various types of peripheral neuropathies, such as traumatic or ischaemic neuropathies, infectious, alcoholic, diabetic, medicinal or genetic neuropathies, and motor neuron conditions, such as
15 spinal amyotrophies and amyotrophic lateral sclerosis. These medicaments will also find an application in the treatment of neurodegenerative diseases of the central nervous system, either of acute type, such as strokes and cranial and medullar traumas, or of chronic type,
20 such as autoimmune diseases (multiple sclerosis), Alzheimer's disease, Parkinson's disease and any other disease in which the administration of neuroprotective/neurotrophic factors is supposed to have a therapeutic effect.

25 The compounds of the invention can also be used for the preparation of medicaments intended for the prevention and/or treatment of anxiety, of epilepsy

and of sleep disorders. This is because ligands of the PBR or p sites stimulate the production of neurosteroids, such as pregnenolone, dehydroepiandrosterone and 3 α -hydroxy-5 α -pregnan-20-one, by promoting
5 the transfer of cholesterol from the outside to the inside of the mitochondrial membrane. These neurosteroids modulate the activity of the GABA_A-chloride channel macromolecular complex and can thus produce anxiolytic, anticonvulsant and sedative
10 activities.

The compounds of the invention can also be used in the treatment of acute or chronic renal insufficiency, of glomerulonephritis, of diabetic nephropathy, of cardiac ischaemia and cardiac
15 insufficiency, of myocardial infarction, of ischaemia of the lower limbs, of coronary vasospasm, of angina pectoris, of pathologies associated with the heart valves, of inflammatory heart diseases, of side effects due to cardiotoxic medicaments or as a result of heart
20 surgery, of atherosclerosis and of its thromboembolic complications, of restenosis, of graft rejections, or of conditions related to incorrect proliferation or incorrect migration of smooth muscle cells.

Furthermore, recent data in the literature
25 indicate that the peripheral-type benzodiazepine receptor might play a fundamental role in the regulation of cell proliferation and cancerization

processes. Generally, and in comparison with normal tissues, an increased density of peripheral-type benzodiazepine receptors is observed in various types of tumours and cancers.

5 In human astrocytomas, the level of expression of the peripheral-type benzodiazepine receptor is correlated with the degree of malignancy of the tumour, the proliferation index and the survival of the patients. In human cerebral tumours, the increase
10 in the number of peripheral-type benzodiazepine receptors is used as a diagnostic indication in medical imaging and as a therapeutic target for conjugates formed from a ligand of the peripheral-type benzodiazepine receptor and from a cytostatic drug. A
15 high density of peripheral-type benzodiazepine receptors is also observed in ovarian carcinomas and breast cancers. As regards the latter, it has been demonstrated that the level of expression of the peripheral-type benzodiazepine receptors is related to
20 the aggressive potential of the tumour; furthermore, the presence of a peripheral-type benzodiazepine receptor agonist stimulates the growth of a mammary cancer line.

 These combined results, which suggest a
25 deleterious function of the peripheral-type benzodiazepine receptor in cancerization processes, constitute a relevant basis for the search for

synthetic ligands specific for the peripheral-type benzodiazepine receptor which are capable of blocking the effects thereof.

The compounds can therefore be used for the
5 treatment of tumours and cancers.

The peripheral-type benzodiazepine receptors are also present in the skin and, in this respect, the compounds which can be used according to the invention can be used for the prophylaxis or the treatment of
10 cutaneous stress.

The term "cutaneous stress" is understood to mean the various situations which might cause damage, in particular to the epidermis, whatever the agent which causes this stress. This agent can be internal
15 and/or external to the body, such as a chemical or free-radical agent, or else external, such as ultraviolet radiation.

Thus, the compounds which can be used according to the invention are intended to prevent and
20 to combat cutaneous irritation, dry patches, erythemas, dysaesthetic sensations, heating sensations, pruritus of the skin and/or mucous membranes, or ageing, and can also be used in cutaneous disorders, such as, for example, psoriasis, pruriginous diseases, herpes,
25 photodermatoses, atopic dermatitides, contact dermatitides, lichens, prurigo, pruritus, insect stings, in fibroses and other disorders of collagen

maturation, in immunological disorders or in dermatological conditions, such as eczema.

The compounds of the invention can also be used for the prevention and treatment of chronic
5 inflammatory diseases, in particular rheumatoid arthritis, and pulmonary inflammatory diseases.

According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, a
10 compound according to the invention. These pharmaceutical compositions comprise an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a hydrate or a solvate of the said compound, and at least one
15 pharmaceutically acceptable excipient. The said excipients are chosen, according to the pharmaceutical form and the method of administration desired, from the usual excipients known to a person skilled in the art.

In the pharmaceutical compositions of the
20 present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active principle of formula (I) above, or its optional salt, solvate or hydrate, can be
25 administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and human beings for the prophylaxis or treatment of

the above disorders or diseases.

The appropriate unit administration forms comprise oral forms, such as tablets, soft or hard gelatin capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants. The compounds according to the invention can be used, for topical application, in creams, gels, ointments or lotions.

By way of example, a unit administration form of a compound according to the invention in the tablet form can comprise the following components:

Compound according to the invention	50.0 mg
Mannitol	223.75 mg
Croscarmellose sodium	6.0 mg
Maize starch	15.0 mg
Hydroxypropylmethylcellulose	2.25 mg
Magnesium stearate	3.0 mg

The said unit forms comprise doses in order to make possible daily administration of 0.001 to 20 mg of active principle per kg of body weight, depending on the pharmaceutical dosage form.

There may be specific cases where higher or lower dosages are appropriate; such dosages do not depart from the scope of the invention. According to

2005251982 26 Oct 2006

- 44 -

the usual practice, the dosage appropriate to each patient is determined by the physician according to the method of administration and the weight and response of the said patient.

- 5 The present invention, according to another of its aspects, also relates to a method for the treatment of the pathologies indicated above which comprises the administration, to a patient, of an effective dose of a compound according to the invention, or one of its
- 10 pharmaceutically acceptable salts or hydrates of solvates.


- Throughout this specification and claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a
- 15 stated integer or group of integers or steps but not the exclusion of any other integer or group of integers.

- The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an
- 20 acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Compound corresponding to the formula

(I)



- 5 in which

W represents an oxygen or sulphur atom;

X₁, X₂, X₃ and X₄ each represent, independently of one another, a hydrogen or halogen atom or a cyano, C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, C₁-C₆-alkoxy or

- 10 C₁-C₆-fluoroalkoxy group;

Y is in the (N2) or (N3) position;

when Y is in the (N2) position, Y represents a

C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, aryl or heteroaryl group;

when Y is in the (N3) position, Y represents an aryl or

- 15 heteroaryl group;

the aryl or heteroaryl groups optionally being

substituted by one or more atoms or groups chosen from halogen atoms or C₁-C₆-alkyl, C₁-C₆-alkoxy,

C₁-C₆-alkylthio, C₁-C₆-alkyl-S(O)-, C₁-C₆-alkyl-S(O)₂- or

- 20 C₁-C₆-fluoroalkyl groups;

the bond in the C4-C5 position is a double or single bond;

R₁ and R₂ each represent, independently of one another, an aryl, benzyl or C₁-C₆-alkyl group; or else R₁ and R₂ form, with the nitrogen atom which carries them, a heterocycle optionally substituted by one or more C₁-C₆-

5 alkyl or benzyl groups;

in the form of the base or of an addition salt with an acid, and in the hydrate or solvate form.

2. Compound of formula (I) according to Claim 1, wherein

10 W represents an oxygen or sulphur atom;

X₁, X₂ and X₃ each represent, independently of one another, a hydrogen atom, a halogen atom, a cyano group, a C₁-C₆-alkyl group or a C₁-C₆-alkoxy group; X₄ represents a hydrogen atom;

15 Y is in the (N2) or (N3) position;

when Y is in the (N2) position, Y represents a C₁-C₆-alkyl group, a C₁-C₆-fluoroalkyl group, an aryl group or a heteroaryl group;

when Y is in the (N3) position, Y represents an aryl group or a heteroaryl group;

20

the aryl or heteroaryl groups optionally being substituted by one or more atoms or groups chosen from halogen atoms, C₁-C₆-alkyl groups and C₁-C₆-alkoxy groups;

25 the bond in the C4-C5 position is a double or single bond;

R₁ and R₂ each represent, independently of one another,

2005251982 31 Mar 2011

C:\9\Pen\ADCC\AMT\3562314_1.DOC-2M3/2011

- 47 -

an aryl group or a C₁-C₆-alkyl group; or else R₁ and R₂ form, with the nitrogen atom which carries them, a heterocycle optionally substituted by one or two C₁-C₆ alkyl groups;

in the form of the base or of an addition salt with an acid, and in the hydrate or solvate form.

3. Compound of formula (I) according to Claim 1 or Claim 2, wherein

W represents an oxygen or sulphur atom;

X₁, X₂ and X₃ each represent, independently of one another, a hydrogen atom, a halogen atom, a C₁-C₆-alkyl group or a C₁-C₆-alkoxy group;

X₄ represents a hydrogen atom;

Y is in the (N2) or (N3) position and represents an aryl group or a heteroaryl group;

the aryl or heteroaryl groups optionally being substituted by one or more atoms or groups chosen from halogen atoms, C₁-C₆-alkyl groups and C₁-C₆-alkoxy groups;

the bond in the C4-C5 position is a double or single bond;

R₁ and R₂ each represent, independently of one another, an aryl group or a C₁-C₆-alkyl group; or else R₁ and R₂ form, with the nitrogen atom which carries them, a heterocycle optionally substituted by one or two C₁-C₆-alkyl groups;

in the form of the base or of an addition salt with an

acid, and in the hydrate or solvate form.

4. Compound of formula (I) according to any one of Claims 1 to 3, wherein

W represents an oxygen or sulphur atom;

5 X₁, X₂ and X₃ each represent, independently of one another, a hydrogen atom, a halogen atom, a C₁-C₆-alkyl group or a C₁-C₆-alkoxy group;

X₄ represents a hydrogen atom;

Y is in the (N3) position and represents an aryl group
10 or a heteroaryl group;

the aryl or heteroaryl groups optionally being substituted by one or more atoms or groups chosen from halogen atoms, C₁-C₆-alkyl groups and C₁-C₆-alkoxy groups;

15 the bond in the C4-C5 position is a double or single bond;


R₁ and R₂ each represent, independently of one another, an aryl group or a C₁-C₆-alkyl group; or else R₁ and R₂ form, with the nitrogen atom which carries them, a

20 heterocycle optionally substituted by one or two C₁-C₆-alkyl groups;


in the form of the base or of an addition salt with an acid, and in the hydrate or solvate form.

5. Process for the preparation of a
25 compound of formula (I) according to any one of Claims 1 to 4, wherein
a mixture composed of the positional isomers of general

formulae (Va) and (Vb),




in which X_1 , X_2 , X_3 , X_4 and Y are as defined in the
 5 general formula (I) according to Claim 1 and in which
 the Y group is respectively in the (N2) position and in
 the (N3) position of the pyrazole ring,
 is reacted with a carbamoyl chloride derivative of
 general formula $ClC(W)NR_1R_2$, in which W , R_1 and R_2 are as
 10 defined in the general formula (I) according to
 Claim 1, in the presence of a base,
 to obtain, after separation, the compounds of general
 formulae (Ia) and (Ib),



15 the single bond in the C4-C5 position subsequently
 being optionally dehydrogenated to form a double bond.

6. Process for the preparation of a

compound of formula (Ia)




in which

- 5 W represents an oxygen or sulphur atom;
 X_1 , X_2 , X_3 and X_4 each represent, independently of one another, a hydrogen or halogen atom or a cyano, C_1 - C_6 -alkyl, C_1 - C_6 -fluoroalkyl, C_1 - C_6 -alkoxy or C_1 - C_6 -fluoroalkoxy group;
- 10 Y is in the (N2) position and represents a C_1 - C_6 -alkyl, C_1 - C_6 -fluoroalkyl, aryl or heteroaryl group;
 the aryl or heteroaryl groups optionally being substituted by one or more atoms or groups chosen from halogen atoms or C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy,
- 15 C_1 - C_6 -alkylthio, C_1 - C_6 -alkyl-S(O)-, C_1 - C_6 -alkyl-S(O)₂- or C_1 - C_6 -fluoroalkyl groups;
 the bond in the C4-C5 position is a double or single bond;
- R_1 and R_2 each represent, independently of one another,
- 20 an aryl, benzyl or C_1 - C_6 -alkyl group; or else R_1 and R_2 form, with the nitrogen atom which carries them, a

heterocycle optionally substituted by a C₁-C₆-alkyl or benzyl group;

wherein the compound of general formula (Va),



5


in which X₁, X₂, X₃, X₄ and Y are as defined in the general formula (Ia) above,

is reacted with a carbamoyl chloride derivative of general formula ClC(W)NR₁R₂, in which W, R₁ and R₂ are as

10 defined in the general formula (Ia) above, in the presence of a base,

the single bond in the C4-C5 position subsequently being optionally dehydrogenated to form a double bond.

7. Compound of formula (Va):



15

in which

X₁, X₂, X₃ and X₄ each represent, independently of one another, a hydrogen or halogen atom or a cyano, C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, C₁-C₆-alkoxy or

C₁-C₆-fluoroalkoxy group;


Y represents a C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, aryl or heteroaryl group;

the aryl or heteroaryl groups optionally being

- 5 substituted by one or more atoms or groups chosen from halogen atoms or C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkyl-S(O)-, C₁-C₆-alkyl-S(O)₂- or C₁-C₆-fluoroalkyl groups.

8. Compound of formula (Vb)

10



in which

X₁, X₂, X₃ and X₄ each represent, independently of one another, a hydrogen or halogen atom or a cyano,

- 15 C₁-C₆-alkyl, C₁-C₆-fluoroalkyl, C₁-C₆-alkoxy or C₁-C₆-fluoroalkoxy group;

Y represents an aryl or heteroaryl group;

the aryl or heteroaryl groups optionally being

- substituted by one or more atoms or groups chosen from
20 halogen atoms or C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkylthio, C₁-C₆-alkyl-S(O)-, C₁-C₆-alkyl-S(O)₂- or C₁-C₆-fluoroalkyl groups.

9. Medicament,

comprising a compound of formula (I) according to any one of Claims 1 to 4, or an addition salt of this compound with a pharmaceutically acceptable acid, or a hydrate or a solvate of the compound of formula (I).

5 10. Pharmaceutical composition, comprising a compound of formula (I) according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, and at least one pharmaceutically acceptable excipient.

10 11. Use of a compound of formula (I) according to any one of Claims 1 to 4 for the preparation of a medicament intended to prevent or treat a pathology in which peripheral-type benzodiazepine receptors are involved.

15 12. Use of a compound of formula (I) according to Claim 11 for the preparation of a medicament intended to prevent or treat peripheral neuropathies, motor neuron conditions, neurodegenerative diseases of the central nervous
20 system, anxiety, epilepsy, sleep disorders, acute or chronic renal insufficiency, glomerulonephritis, diabetic nephropathy, cardiac ischaemia and cardiac insufficiency, myocardial infarction, ischaemia of the lower limbs, coronary vasospasm, angina pectoris,
25 pathologies associated with the heart valves, inflammatory heart diseases, side effects due to

2005251982 31 Mar 2011

- 54 -

cardiotoxic medicaments or as a result of heart surgery, atherosclerosis and its thromboembolic complications, restenosis, graft rejections, conditions related to incorrect proliferation or incorrect migration of smooth muscle cells, tumours and cancers, cutaneous stress, chronic inflammatory diseases, in particular rheumatoid arthritis, and pulmonary inflammatory diseases.

13. A compound, pharmaceutical composition, medicament process for preparation of a compound or the use of a compound substantially as hereinbefore described with reference to any one of the examples.

14. Method of treatment or prevention of a pathology in which peripheral-type benzodiazepine receptors are involved comprising administering an effective amount of a compound according to claim 1 in pharmaceutically acceptable form of a base, acid addition salt, hydrate or solvate.

15. Method of treatment or prevention of peripheral neuropathies, motor neuron conditions, neurodegenerative diseases of the central nervous system, anxiety, epilepsy, sleep disorders, acute or chronic renal insufficiency, glomerulonephritis, diabetic nephropathy, cardiac ischaemia and cardiac insufficiency, myocardial infarction, ischaemia of the lower limbs, coronary vasospasm, angina pectoris, pathologies associated with the heart valves, inflammatory heart diseases, side effects due to cardiotoxic medicaments or

2005251982 31 Mar 2011

- 55 -

as a result of heart surgery, atherosclerosis and its thromboembolic complications, restenosis, graft rejections, conditions related to incorrect proliferation or incorrect migration of smooth muscle cells, tumours and cancers, cutaneous stress, chronic inflammatory diseases, in particular rheumatoid arthritis, and pulmonary inflammatory diseases comprising administering an effective amount of a compound according to claim 1 in pharmaceutically acceptable form of a base, acid addition salt, hydrate or solvate.